Recombinant Human Endothelial-MonocyteAActivating Polypeptide II (rHuEMAP-II)
EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.
Product Specifications
Source
Escherichia coli.
Field of Research
Cardiovascular Research
Endotoxin
Less than 1EU/mg of rHuEMAP-II as determined by LAL method.
Purity
>98% by SDS-PAGE and HPLC analyses.
Bioactivity
Determined by the apoptotic effect on MCF-7 cells using a concentration of 20-40 ng/ml, corresponding to a Specific Activity of >2.5 x 104 IU/mg.
Form
Lyophilized from a 0.2mm filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.
Molecular Weight
Approximately 18.3 KDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
Storage Conditions
Notes
For research use only.
Applications Notes
Preservative
Lyophilized from a 0.2mm filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.
AA Sequence
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
